186 results about "Serum protein" patented technology

The invention relates to a chemiluminescence kit for detecting pepsinogen II. The kit comprises an enzyme marker, a luminescent substrate solution and an anti-interference buffer system, the anti-interference buffer system comprises a nonionic surfactant, animal-derived IgG (immunoglobulin G), an antioxidant and catalase; the chemiluminescence kit also comprises a PG II calibration product and a PG II quality control product. The core active component of the enzyme marker is beta-galactosidase. The enzyme marker further comprises an anti-PG II monoclonal antibody marked by beta-galactosidase, bovine serum albumin, trehalose, cane sugar, MgCl2. 6H2O, sodium chloride, Proclin300 and a phosphate buffer solution. According to the kit, a brand-new anti-interference buffer system is introduced on the basis of a spatial proximity chemiluminescence analysis method, so that the resistance to clinically common interferents (such as hemolysis, lipemia, jaundice and heterotropism antibodies) is remarkably improved, and the detection result is more accurate and reliable.

The invention discloses a brain nerve cell targeted gene protein co-loaded nano delivery system and a preparation method thereof, phenylboronic acid modified polyethyleneimine is synthesized through substitution reaction, then the polyethyleneimine is compounded with DNA through electrostatic interaction to form a PEI-PBA / DNA nano compound, bovine serum albumin is loaded through nitrogen-boron complexation, and the brain nerve cell targeted gene protein co-loaded nano delivery system is obtained. The preparation method comprises the following steps: preparing a gene-protein co-loaded nano delivery system PPDB, further endowing the nano delivery system with a function of crossing a blood brain barrier, and introducing glycerophosphorylcholine through the formation of a borate bond, so as to prepare the cerebral nerve cell targeted gene-protein co-loaded nano system PPDBG. The preparation method disclosed by the invention is simple, realizes simultaneous loading of genes and proteins with completely different physical structures, and has very important research significance on brain-related diseases such as epilepsy and the like. Meanwhile, the introduction of the boric acid ester bond endows the nano delivery system with the on-demand plug-and-play characteristic, so that the spectral applicability of the nano delivery system is realized.

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

The utility model relates to a bovine serum albumin purification device, and aims to improve the dropping precision of a salt solution in a protein purification process through automatic design and accurate control. The device comprises a pump box, a conveying wheel set, a liquid conveying rubber pipe, a driving motor and a liquid storage tank. The driving motor drives the conveying wheel set to rotate, and the abutting roller in the conveying wheel set revolves around the main shaft sleeve to extrude the liquid feeding rubber pipe, so that the salt solution is pushed to move along the pipeline, and accurate dripping of the liquid is realized. A groove gland is arranged on one side of the pump box and used for pressing the liquid conveying rubber pipe when the conveying wheel set is not started, and liquid leakage is prevented. The arrangement of the adjusting disc allows the abutting roller to be adjusted in the radial direction so as to adapt to liquid feeding rubber pipes of different specifications, and therefore the output amount of the salt solution is accurately controlled. The device is simple in structure and convenient to operate, can effectively improve the purification efficiency and quality of bovine serum albumin, and is suitable for various experiments and production environments.

The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.

The application belongs to the technical field of biomedical engineering, and specifically discloses a nano gene composition for treating brain glioma and a preparation method thereof, which is synthesized from bovine serum albumin loaded manganese dioxide particles, PLGA, DSPE-PEG3000 and DSPE-PEG-Angiopep2 as raw materials; the average particle size of the nano gene composition is 122.18±31.3 nm. The application also discloses a preparation method of the nano gene composition. The nano gene composition provided by the application encapsulates miRNA-138 in PLGA to avoid the degradation of miRNA-138 by RNA enzymes in the body, and simultaneously utilizes the targeting property of Angiopep2 to target the delivery of the nano gene composition to tumor tissues, to deliver microRNA into the brain while reducing tumor hypoxia and increasing the sensitivity of cells to X-ray irradiation, so as to realize multidirectional comprehensive treatment of glioblastoma.

The application discloses a preparation method and application of a polyacid tannic acid modified ultrafiltration membrane, and the preparation method comprises the following steps: preparing a casting solution containing a high molecular film forming material and a solvent; adding a polyoxometalate into the casting solution, uniformly mixing, and obtaining a polyacid modified casting solution; scraping and coating the polyacid modified casting solution to form a liquid membrane, pre-evaporating, immersing into a coagulation bath containing tannic acid to perform phase inversion and film forming, and obtaining the polyacid tannic acid modified ultrafiltration membrane. Through the synergistic effect of the polyacid blending regulation of the membrane pore structure and the in-situ coordination modification of the tannic acid phase separation, the simultaneous improvement of the permeation flux and the retention rate is realized, the pure water flux of the obtained ultrafiltration membrane reaches 221.37 LMH, the bovine serum albumin retention rate reaches 96.17%, and the preparation process is simple, efficient, and has a good large-scale application prospect.

The application discloses a micro serum tumor whole-process screening detection method based on nucleic acid aptamer group comparison, and comprises the following steps: firstly, 24+1 tumor and non-tumor specific nucleic acid aptamer groups are screened by using bidirectional thermal cycle subtraction SELEX technology; data of the specific nucleic acid aptamer groups are used to create a standard database; the specific nucleic acid aptamer groups are mixed in equal proportions to develop 24+1 tumor and non-tumor specific nucleic acid aptamer detection reagents; in the detection process, the detected sample forms a magnetic bead-sample serum protein complex, and then is combined with the aptamer detection reagent; a magnetic bead-serum protein-sample specific nucleic acid aptamer complex is formed, and sample specific nucleic acid aptamer is separated and obtained; and the sample specific nucleic acid aptamer is compared and analyzed with the standard database, so that the sample detection technology method is realized. The method has the advantages of small sample amount, automatic process completion, high throughput, wide tumor screening range and the like, and meets the requirements of high-throughput tumor screening.

The present disclosure relates to collagen binding modification engineering of anti-inflammatory agents using collagen binding peptides (CBP) and vWF A3 to achieve targeted therapy of inflammatory diseases. Accordingly, embodiments of the present disclosure relate to compositions comprising an anti-inflammatory agent operably linked to an extracellular matrix (ECM) affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to serum proteins and / or ECM affinity peptides. Other aspects of the present disclosure relate to methods for treating an autoimmune or inflammatory disorder in a subject comprising administering to the subject a composition of the present disclosure.

The application belongs to the field of biotechnology, and particularly relates to application of UBQLN1 protein in a cirrhosis diagnosis product, a kit and an in vitro detection method. The application comprises: using serum UBQLN1 protein as a marker, and applying the marker in preparation of a product for diagnosing or assisting in diagnosing cirrhosis; or applying the marker in preparation of a product for distinguishing cirrhosis from healthy individuals; or applying the marker in preparation of a product for evaluating progression of cirrhosis or a degree of liver fibrosis; and applying the marker in screening or evaluating a drug for preventing and / or treating cirrhosis.

The invention discloses a supramolecular fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of nano material application. The supramolecular fluorescent probe is formed by compounding gold nanoclusters and a bovine serum albumin solution, and the concentration ratio of the gold nanoclusters to the bovine serum albumin solution is (1-2): (2-4). The invention further discloses a preparation method of the supramolecular fluorescent probe and application of the supramolecular fluorescent probe. A fluorescent sensing system of the supramolecular fluorescent probe based on the gold nanocluster material and the bovine serum albumin has excellent selectivity and sensitivity on cypermethrin pesticide, interference of other impurities can be effectively avoided, and response is fast.

The application discloses a kind of ratio fluorescent sensor based on smart phone and its preparation method and application, the preparation method includes: after mixing chloroauric acid, bovine serum albumin, sodium hydroxide, gold cluster reaction liquid is obtained;Sodium citrate, 3-aminopropyl triethoxysilane, glycerol are mixed to obtain silicon quantum dot solution;Silicon quantum dot solution, lipopolysaccharide aptamer, EDC, NHS are reacted in ultrapure water to obtain aptamer modified silicon quantum dots;Lipopolysaccharide aptamer modified silicon quantum dots and gold cluster are mixed to obtain ratio fluorescent sensor.The ratio fluorescent sensor based on smart phone prepared by the application has good stability, strong specificity, can exclude fluorescent interference in environmental matrix, and is used for lipopolysaccharide analysis and detection by combining the colorimetric analysis of color picker of smart phone, so that in-vitro naked-eye visible rapid quantitative detection of lipopolysaccharide can be realized, to meet the demand of on-site monitoring.

The invention provides a biomarker for diagnosing primary biliary cholangitis and application of the biomarker, and belongs to the technical field of biomarkers. The biomarker disclosed by the invention comprises serum protein and / or N-glycopeptide. According to the method, the improvement of PBC diagnosis is taken as a starting point, the serum protein and the N-glycopeptide are taken as screening templates, a more accurate non-invasive prediction means for differential diagnosis of PBC is provided, and a theoretical basis is provided for rapid and accurate diagnosis of PBC.

The utility model relates to the technical field of cosmetic packaging, in particular to a serum protein active water film vacuum fresh-keeping glass bottle packaging device. The device comprises a storage assembly and a pumping assembly, the pumping assembly is connected with the storage assembly and extracts objects stored in the storage assembly outwards, the pumping assembly is externally connected with a smearing assembly, sealing assemblies are installed on the storage assembly and the smearing assembly, and the sealing assemblies control opening and closing installation. The storage assembly is designed to be in vacuum sealing, contact between oxygen in air and a serum protein active water film is remarkably reduced, the oxidation risk is reduced, the shelf life of the product is prolonged, the pumping assembly can accurately control the dosage extracted each time, waste is avoided, meanwhile, it is ensured that the dosage used each time is consistent, and the service life of the product is prolonged. The pumping mechanism reduces the opportunity that fingers of a user make direct contact with the product, pollution risks are reduced, product sanitation is guaranteed, the external smearing assembly is designed to be suitable for direct use, intermediate operation steps are reduced, and the user can smear the product easily.

The invention discloses a method for analyzing serum differential expression protein characteristics of an AQP4-IgG positive NMOSD patient, and relates to the technical field of differential expression protein characteristic analysis, and the method comprises the following steps: S1, collecting a serum sample of a to-be-detected subject; s2, carrying out protein detection on the serum sample to obtain expression level data of at least one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8, wherein the expression level data is one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8; s3, carrying out comparative analysis on the expression level of the serum protein and a pre-established AQP4-IgG positive NMOSD serum protein expression characteristic reference standard; according to the method for auxiliary diagnosis of the AQP4-IgG positive neuromyelitis optica pedigree disease provided by the invention, a judgment mode capable of reflecting molecular characteristics of the AQP4-IgG positive neuromyelitis optica pedigree disease is constructed by carrying out conjoint analysis on various serum protein expression characteristics related to immunoregulation, inflammatory response, complement activation and metabolism; therefore, the problem of insufficient detection stability of a single biomarker is avoided.

The subject invention provides a composition comprising an enomomer which comprises a) a carrier molecule, and b) at least one aptamer, wherein the carrier molecule is an antibody, an antigen-binding moiety, a serum protein, an intracellular protein, a messenger RNA (mRNA) or human serum albumin.

The invention discloses an abdominal aortic aneurysm serum protein fingerprint detection and analysis method and system based on an LASSO regression algorithm. The method comprises the following steps: by optimizing a serum sample pretreatment process and combining an MALDI-TOFMS (Matrix-Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry) mass spectrometry technology and high-throughput proteomics data analysis, screening differentially expressed proteins related to occurrence, development and rupture of abdominal aortic aneurysm in serum; and further constructing a risk assessment model based on the key protein combination by using an LASSO machine learning algorithm. The method provided by the invention has the advantages of high sensitivity and good specificity, can effectively distinguish abdominal aortic aneurysm patients from normal people, can accurately predict the rupture risk of abdominal aortic aneurysm, especially early small aneurysm, and provides important tools and bases for clinical early diagnosis, risk stratification and personalized treatment decision.

The present application relates to the technical field of separation and extraction, and particularly relates to a separation device for serum protein extraction, which comprises a reaction tank and a stirring rod, the stirring rod is provided with stirring blades rotating with the stirring rod, the reaction tank is fixedly provided with a stirring motor, and the separation device further comprises: a driving shaft vertically arranged in the reaction tank and deviated from the central position of the reaction tank, the stirring motor is used for driving the driving shaft to rotate; a mounting frame comprising a first connecting part and a second connecting part, the first connecting part is sleeved on the driving shaft and rotationally connected with the driving shaft, and the second connecting part is used for rotationally mounting the stirring rod; a transmission assembly is arranged between the driving shaft and the stirring rod, the stirring rod is driven to rotate by the driving shaft; and a driving assembly is used for driving the first connecting part to rotate, so that the stirring rod swings around the driving shaft. The stirring rod is stirred during swinging in the reaction tank, the uniformity of mixing is improved, and the problem of local over-acidification is reduced.

This invention provides a serum protein biomarker for early screening and diagnosis of pancreatic ductal adenocarcinoma. The serum protein biomarker is one or a combination of two or more autoantibodies against tumor-associated antigens HEXB, TXLNA, and SLAMF6. The invention also provides the application of reagents, kits, and analytical methods for detecting the serum protein biomarker. This invention screens for autoantibodies against pancreatic ductal adenocarcinoma-associated antigens. By measuring the expression levels of these indicators in the serum of patients with pancreatic ductal adenocarcinoma, healthy controls, and controls with benign pancreatic diseases, the screened anti-HEXB, anti-TXLNA, and anti-SLAMF6 autoantibodies can distinguish between pancreatic ductal adenocarcinoma, healthy controls, and benign pancreatic diseases. Furthermore, this invention designs and optimizes combinations of tumor-associated antigens for the diagnosis of pancreatic ductal adenocarcinoma. Applying the optimized antigens to an ELISA kit and detecting serum anti-TAA autoantibodies using an indirect enzyme-linked immunosorbent assay (ELISA) can accurately identify patients with pancreatic ductal adenocarcinoma, healthy controls, and patients with benign pancreatic diseases.

The invention discloses a serum protein marker combination for detecting cerebral microhemorrhage, and belongs to the field of biological medicine detection.The serum protein marker combination comprises four serum proteins including matrix metalloproteinase 3, fibronectin-like extracellular matrix protein 1 containing epidermal growth factors, a metalloproteinase inhibiting factor 1 and uromodulin; through efficient and accurate serum protein marker combination, the defects that brain function magnetic resonance SWI examination is high in cost and long in time consumption, operation depends on high-level imaging physicians and the like are overcome, an innovative tool is provided for rapid, accurate and non-invasive screening and auxiliary diagnosis of cerebral microhemorrhage, and wide clinical application prospects are achieved.

The invention provides a reinforcing agent diluent suitable for an immunohistochemical stainer and a use method, and particularly relates to the technical field of immunodetection. The invention discloses a fresh keeping agent which is prepared from the following components in percentage by mass: 0.1 to 1 percent of Tris, 0.1 to 1 percent of sodium chloride, 0.01 to 0.1 percent of magnesium sulfate, 0.01 to 0.05 percent of Tween-20, 1 to 5 percent of trehalose, 0.01 to 0.05 percent of PC300 preservative, 0.5 to 1.5 percent of bovine serum albumin (BSA), 0.01 to 0.05 percent of casein, 0.01 to 0.05 percent of polyethylene oxide (PEO) and the balance of pure water, wherein the mass fraction of the Tris is 0.1 to 1 percent; the mass fraction of the magnesium sulfate is 0.01 to 0.1 percent; the volume fraction of the Tween-20 is 0.01 to 0.05 percent; the enhancer diluent disclosed by the invention is more suitable for a full-automatic immunohistochemical instrument, and has the advantages of better film preparation effect, higher dyeing intensity and no obvious non-specific coloring.

The invention relates to the field of cell culture, in particular to an epimatrix for three-dimensional cell culture and a preparation method of the epimatrix. The external matrix comprises xanthan gum, polyvinyl alcohol methyl acrylate, serum protein, arginine, trehalose, mannitol, dimethyl sulfoxide, ethylene glycol and a bacteriostatic agent. During preparation, dimethyl sulfoxide and ethylene glycol are mixed firstly, serum protein and an aqueous solution of xanthan gum are sequentially added to the surface layer of the mixture, oxygen is introduced from the bottom layer of the mixture, and a first precursor solution is obtained; introducing carbon dioxide into the bottom layer of a mixed aqueous solution of trehalose, mannitol and arginine to obtain a second precursor solution; after the first precursor solution and the second precursor solution are uniformly mixed, the polyvinyl alcohol methyl acrylate and the bacteriostatic agent are added and uniformly mixed again to obtain the epimatrix, and the epimatrix highly simulates the epimatrix in the human liver tissue and is beneficial to construction of cell spheres or complex tissue structures closer to the in-vivo physiological state.

4-methyl-1, 2, 3-thiadiazole-5-formic acid (HT) is used as a ligand and reacts with lanthanum nitrate hexahydrate to synthesize the thiadiazole lanthanum complex [LaT3. (H2O) 2] n, the structure of the complex is characterized through single crystal-X-ray diffraction, infrared spectroscopy, elemental analysis, ultraviolet spectroscopy and thermogravimetric analysis, the fluorescence performance of the complex is measured, and the thiadiazole lanthanum complex is obtained. The interaction of the lanthanum complex with calf thymus DNA (CT-DNA) and human serum albumin (HSA) is researched through ultraviolet and fluorescence spectra. The coordination compound belongs to a triclinic crystal and a Pi space group. Research on the biological activity of the lanthanum complex shows that the lanthanum complex shows good biological activity, and can be beneficial to development of novel antibacterial drugs, help to promote research and development of anti-cancer drugs and enrich the content of medicinal chemistry and pharmacology. Different types of compounds are combined or have a synergistic effect, so that a novel medicine with unique performance and advantages is developed.

This invention relates to a method for producing serum protein concentrate, wherein at least one of the microbial reduction steps includes treatment with UV-C radiation, thereby increasing the content of heat-sensitive bioactive components and improving the sustainability of the serum protein concentrate production method.

The application belongs to the technical field of membrane separation, and particularly relates to a small-aperture high-flux ultrafiltration membrane and a preparation method and application thereof. Polymer material, an additive and an organic solvent are mixed, constant-temperature stirring and standing defoaming are performed to obtain a casting solution, and then a non-solvent phase separation method is used to prepare the ultrafiltration membrane. The polymer material comprises polyethersulfone and sulfonated polyphenylsulfone with a mass ratio of 95:5-80:20, and the additive is polyethylene glycol. The rejection rate of the ultrafiltration membrane to bovine serum albumin (BSA) is above 99%, the rejection rate of direct red 23 and coomassie brilliant blue and other dyes can be above 96%, and the pure water permeability is 310 L·m ‑2 ·h ‑1 ·bar ‑1 , which has a wide application prospect in the fields of antibody protein purification and concentration, dye desalination and nanoscale pollutant treatment in wastewater.

The invention belongs to the technical field of biomarker detection, and particularly relates to a method for synchronously and quantitatively detecting urotoxin p-cresol sulfate and indoxyl sulfate based on LC-MS / MS of an alternative analyte method and application. According to the method, stable isotope labeled pCS-d4 and INDS-d4 are creatively adopted as alternative analytes, pCS-d7 and INDS-13C6 are adopted as internal labels, a protein binding state target object is released through serum protein precipitation, a free state target object is obtained through an ultrafiltration method, a universal reversed-phase C18 chromatographic column is adopted for gradient elution and separation, and the detection result is accurate. An organic solvent containing ammonium acetate, formic acid aqueous solution-methanol and the like is used as a mobile phase, and a dual specific detection system for the total content and the free state content of the target object in the serum is established through a multi-reaction monitoring (MRM) mode of LC-MS / MS. The problem of accurate quantification of the nephropathy biomarker in a biological sample under the condition of no blank matrix is solved in a breakthrough manner, and key data support is provided for evaluating pathological toxicity risk of urotoxin.

The anti-cancer use of a camptothecin derivative which demonstrates a surprising resistance to the degrading effects of Human Serum Albumin ("HSA") in vivo is disclosed. Since HSA represents about half of serum protein in human blood, previous camptothecins generally worked poorly or not at all in vivo due to inactivation by HSA among other factors. Since NSS-01 is similar in mechanism of action to other camptothecins, and as demonstrated herein has both: (i) greater anti-tumor activity against various human cancers and (ii) less toxicity at therapeutic dosing - than topotecan and irinotecan; and without wishing to be bound by theory, NSS-01 demonstrated desirable antitumor activity against adenocarcinomas, it therefore should demonstrate desirable antitumor activity against other cancers that are susceptible to Topoisomerase I inhibitors.

The present invention belongs to the field of electrochemical detection technology and relates to a new anti-fouling material OPA-CsPbBr3, its preparation method, and sensing application. The present invention forms the anti-fouling material OPA-CsPbBr3 by doping OPA polymer into CsPbBr3. On the one hand, due to the good hydrophilicity and near-neutrality of OPA, it exhibits excellent anti-fouling performance; on the other hand, it can further improve the water stability of CsPbBr3, so that it exhibits excellent glucose oxidase-like activity. The present invention further provides an anti-fouling electrochemical biosensor using OPA-CsPbBr3 as an anti-fouling material and peptide nucleic acids (PNAs) as sensing probes. The sensor can effectively resist the nonspecific adsorption of biological molecules such as proteins in complex biological samples (such as blood and serum). In addition, the integrated nanozyme cascade catalysis and CRISPR / Cas13a system further enhance the detection sensitivity of the anti-fouling electrochemical biosensor, enabling sensitive detection of miRNA-let-7a in complex biological samples.

The invention discloses an oral lichen planus molecular subtype based on a serum protein marker. The molecular typing is based on a multi-center clinical queue, a new molecular typing is obtained by using transcriptome sequencing data through a Seed-Kmeans semi-supervised clustering algorithm, and a serum marker is further screened out through multiple omics data including the transcriptome sequencing data, proteome sequencing data and serum enzyme-linked immunosorbent assay experimental data. The method can be used for further judging molecular typing. The molecular typing can obviously improve the curative effect of the oral lichen planus medicine, and is beneficial to the realization of OLP individualized precision medical treatment.

The invention belongs to the technical field of medical detection and biological medicine, and discloses a serum protein marker combination for glioma diagnosis and prognosis evaluation and a processing system of the serum protein marker combination. Eight algorithms including KNN, SVM, random forest, XGBoost, AdaBoost, LGBM, Gaussian naive Bayes and decision tree cover traditional machine learning and integrated learning, and model robustness is improved; according to the method, interpretable feature screening is adopted, SHAP and LIME tools are combined, the contribution degree of each marker to a diagnosis result is clarified, and the problem of'black box 'of machine learning is solved; the invention provides a machine learning algorithm-based mass spectrometry system for glioma detection, which is good in detection performance, high in speed, convenient to operate and low in cost, so as to meet the requirements of clinical early diagnosis and non-invasive examination of glioma.